$1.69
3.98%
Nasdaq, Aug 29, 10:49 pm CET
ISIN
US98943L1070
Symbol
ZNTL

Zentalis Pharmaceuticals Inc Stock price

$1.69
+0.34 25.19% 1M
-0.38 18.36% 6M
-1.34 44.22% YTD
-1.56 48.00% 1Y
-23.44 93.28% 3Y
-32.71 95.09% 5Y
-21.51 92.72% 10Y
-21.51 92.72% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.07 3.98%
ISIN
US98943L1070
Symbol
ZNTL
Industry

Key metrics

Basic
Market capitalization
$131.3m
Enterprise Value
$-172.1m
Net debt
positive
Cash
$303.4m
Shares outstanding
72.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.9 | -
EV/Sales
negative | -
EV/FCF
1.1
P/B
0.5
Financial Health
Equity Ratio
78.4%
Return on Equity
-49.2%
ROCE
-54.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$26.9m | $0.0
EBITDA
$-169.2m | $-267.4m
EBIT
$-170.3m | $-180.6m
Net Income
$-162.8m | $-159.0m
Free Cash Flow
$-151.1m
Growth (TTM | estimate)
Revenue
-33.8% | -100.0%
EBITDA
22.8% | -43.6%
EBIT
22.8% | 3.7%
Net Income
16.4% | 4.1%
Free Cash Flow
9.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-629.9% | -
EBIT
-633.8%
Net
-605.9% | -
Free Cash Flow
-562.4%
More
EPS
$-2.3
FCF per Share
$-2.1
Short interest
7.7%
Employees
166
Rev per Employee
$410.0k
Show more

Is Zentalis Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Zentalis Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:

9x Buy
60%
6x Hold
40%

Analyst Opinions

15 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:

Buy
60%
Hold
40%

Financial data from Zentalis Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
27 27
34% 34%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 74 74
14% 14%
274%
- Research and Development Expense 124 124
37% 37%
460%
-169 -169
23% 23%
-630%
- Depreciation and Amortization 1.06 1.06
21% 21%
4%
EBIT (Operating Income) EBIT -170 -170
23% 23%
-634%
Net Profit -163 -163
16% 16%
-606%

In millions USD.

Don't miss a Thing! We will send you all news about Zentalis Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zentalis Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
5 days ago
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
7 days ago
Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise
Neutral
The Motley Fool
26 days ago
Zentalis Pharmaceuticals (ZNTL -2.13%), a clinical-stage biopharmaceutical company focused on developing cancer therapies, released its second quarter earnings on August 6, 2025. The headline news was a much narrower net loss per share than forecast: it posted a GAAP EPS of $0.37 for Q2 2025, better than analyst projections of a $(0.59) loss.
More Zentalis Pharmaceuticals Inc News

Company Profile

Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.

Head office United States
CEO Julia Eastland
Employees 166
Founded 2014
Website www.zentalis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today